Edwards Lifesciences Gross Unrealized Gains decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $100.00K to $0.00. Over 5 years (FY 2020 to FY 2025), Gross Unrealized Gains shows a downward trend with a -51.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher unrealized gains generally indicate a favorable interest rate environment or strong performance of the underlying assets.
This metric tracks the total gross unrealized gains on debt securities classified as available-for-sale. It represents t...
This metric is highly sensitive to market interest rates and is a standard disclosure for all banks with large investment portfolios.
other_available_for_sale_debt_securities_accumulated_gro_8d5dbc| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.60M | $6.20M | $2.90M | $200.00K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $100.00K | $100.00K | $100.00K | $100.00K | $200.00K | $200.00K | $100.00K | $100.00K | $200.00K | $300.00K | $0.00 |
| QoQ Change | — | -18.4% | -53.2% | -93.1% | -100.0% | — | — | — | — | — | +0.0% | +0.0% | +0.0% | +100.0% | +0.0% | -50.0% | +0.0% | +100.0% | +50.0% | -100.0% |
| YoY Change | — | — | — | — | -100.0% | -100.0% | -100.0% | -100.0% | — | — | — | — | — | +100.0% | +100.0% | +0.0% | +0.0% | +0.0% | +50.0% | -100.0% |